NCT04156685View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 6, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

October 2, 2019

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

Part A, Reference (D635 10/500mg, Astrazeneca)

Once a day. Under fasting condition

DRUG

Part A, Reference (D635 10/500mg, Astrazeneca)

Once a day. Under fasting condition

DRUG

Part B, Reference (D635 10/500mg, Astrazeneca)

Once a day. Under fed condition

DRUG

Part B, Reference (D635 10/500mg, Astrazeneca)

Once a day. Under fed condition

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY